Infant exposure to Fluvoxamine through placenta and human milk: a case series - A contribution from the ConcePTION project.

Autor:	Monfort A; CHU Sainte-Justine, Montréal, QC, Canada.; Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada., Cardoso E; Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Eap CB; Center for Research and Innovation in Clinical Pharmaceutical Sciences, University Hospital and University of Lausanne, Lausanne, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Switzerland.; Unit of Pharmacogenetics and Clinical Psychopharmacology, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland., Fischer Fumeaux CJ; Clinic of Neonatology, Department Mother-Woman-Child, Lausanne University Hospital, Lausanne, Switzerland., Graz MB; Clinic of Neonatology, Department Mother-Woman-Child, Lausanne University Hospital, Lausanne, Switzerland., Morisod Harari M; Division of Child and Adolescent Psychiatry, Lausanne University Hospital, Lausanne, Switzerland., Weisskopf E; Center for Research and Innovation in Clinical Pharmaceutical Sciences, University Hospital and University of Lausanne, Lausanne, Switzerland., Gandia P; Laboratory of Pharmacokinetics and Toxicology, Purpan Hospital, University Hospital of Toulouse, Toulouse, France., Allegaert K; Child and Youth Institute, KU Leuven, Leuven, Belgium.; Department of Development and Regeneration, KU Leuven, Leuven, Belgium.; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.; Department of Hospital Pharmacy, Erasmus MC, Rotterdam, Netherlands., Nordeng H; Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.; Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway., Hascoët JM; Department of Neonatology, Maternité Régionale, Université de Lorraine, Nancy, France., Claris O; Department of Neonatology, Hospices Civils de Lyon, Lyon, France.; Claude Bernard University, P2S 4129, Lyon, France., Epiney M; Department of Women, Child and Adolescent, Geneva University Hospital, Geneva, Switzerland., Csajka C; Center for Research and Innovation in Clinical Pharmaceutical Sciences, University Hospital and University of Lausanne, Lausanne, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Switzerland., Guidi M; Center for Research and Innovation in Clinical Pharmaceutical Sciences, University Hospital and University of Lausanne, Lausanne, Switzerland.; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Ferreira E; CHU Sainte-Justine, Montréal, QC, Canada.; Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada., Panchaud A; Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Jazyk:	angličtina
Zdroj:	Frontiers in psychiatry [Front Psychiatry] 2023 May 18; Vol. 14, pp. 1167870. Date of Electronic Publication: 2023 May 18 (Print Publication: 2023).
DOI:	10.3389/fpsyt.2023.1167870
Abstrakt:	Introduction: Fluvoxamine is widely used to treat depression during pregnancy and lactation. However, limited data are available on its transfer to the fetus or in human milk. This case series provides additional information on the infant exposure to fluvoxamine during pregnancy and lactation. Case Presentation: Two women, aged 38 and 34 years, diagnosed with depression were treated with 50 mg fluvoxamine during pregnancy and lactation. At delivery a paired maternal and cord blood sample was collected for each woman. The first mother exclusively breastfed her child for 4 months and gave one foremilk and one hindmilk sample at 2 days and 4 weeks post-partum, whereas the second mother did not breastfeed. Results: The cord to plasma concentration ratios were 0.62 and 0.48, respectively. At 2 weeks post-partum, relative infant doses (RID) were 0.47 and 0.57% based on fluvoxamine concentrations in foremilk and hindmilk, respectively. At 4 weeks post-partum, the RIDs were 0.35 and 0.90%, respectively. The child from the first mother was born healthy and showed a normal development at the 6th, 18th and 36th month follow-ups. One of the twins from the second woman was hospitalized for hypoglycemia that was attributed to gestational diabetes and low birth weight. The second one was born healthy. Conclusion: These results suggest a minimal exposure to fluvoxamine during lactation which is in accordance with previously published data. Larger clinical and pharmacokinetic studies assessing the long-term safety of this drug during lactation and the variability of its exposure through breastmilk are warranted. Competing Interests: The innovative Medicines Initiative is an EU public-private partnership funding health research and innovation. (Copyright © 2023 Monfort, Cardoso, Eap, Fischer Fumeaux, Graz, Morisod Harari, Weisskopf, Gandia, Allegaert, Nordeng, Hascoët, Claris, Epiney, Csajka, Guidi, Ferreira and Panchaud.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu